Next Phase Newsletter

A venture capital arm of a global pharmaceutical company with a market cap exceeding $8 million, is actively investing in the early-stage healthcare sector. The firm focuses on seed-stage opportunities, with the initial investment range broadly, spanning up to several million. The firm is interested in opportunities globally with a focus in the US. The firm is open to both leading and co-investing and will consider board seats when leading the round. While the firm is mostly financial driven, the firm is able to bring in the strategic perspective if deemed necessary. 
 
The firm seeks companies with innovative sciences addressing highly unmet needs. The firm is focused on therapeutic, including cell and gene therapy, small molecules, radiopharmaceuticals, CRISPR, and data-driven technologies such as AI-driven drug discovery. The firm is interested in oncology, neurology, and rare diseases. Less invasive diagnostic technologies are also within the scope. The firm mostly works with companies in the preclinical to phase I stages. 
 
The firm focuses on finding promising science backed by strong IP. As an active investor, the firm supports portfolio companies through its extensive network and resources. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A global angel investment group was created to leverage cross-pacific business opportunities by investing in early stage life science and healthcare companies, with an Asia connection. The firm invests in companies that are interested in performing development work in China, or commercializing their products in Asia;  the firm makes use of relationships with Asia-based life science service providers to guide portfolio companies through the development process , and also assists companies with the Chinese regulatory process. The firm is pre-venture capital and can contribute business, scientific and regional expertise to companies to improve probability for success. 
 
The firm will consider opportunities across the life science space, and is primarily focused on diagnostics and devices but also invests in therapeutics and life science tools.  The firm generally invests in companies with products with strong animal data, and which are addressing a significant health problem in China (such as cancer, cardiovascular and metabolic diseases, infectious diseases, and also CNS disorders in some circumstances).  Companies which have already attained approval in a market outside China may be of interest. 
 
The firm invests in early stage deals.  The firm only invests in companies that are interested in performing development work in China, or commercializing their products in China; the firm makes use of relationships with China-based life science service providers to guide portfolio companies through the development process and obtain matching government funds in China, and also assists companies with the Chinese regulatory process. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

An impact investor focused on pediatric indications is willing to invest in companies in therapeutics, diagnostics, medical devices or digital health that help improve pediatric care. As an impact fund, the firm donates 10% of the General Partner’s Carry Interest to fund pediatric research. The firm generally makes initial investments of $3-5M and will invest globally. The firm looks to invest in 12-15 companies out of their first fund. 
 
Within pediatric indications, the firm is interested in Oncology, Infectious Diseases and select Rare/Orphan indications. The firm will consider any technology that helps move care forward in these areas, either directly, as a therapeutic or other treatment device or diagnostic, or indirectly, as a digital health technology that helps support care or complements treatment. For therapeutics, the firm will invest in companies that are 12-18 months from IND. For diagnostics and medical devices, the firm would like to see a proof of concept or prototype. For digital health, some post pilot sales or evidence of market traction is preferred, as is a partnership with a strategic partner, with validation of the technology. 
 
The firm can lead or co-invest, and looks to be a board observer for every portfolio company. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

Established in 2021, a USA-based venture capital firm is specialized in investments within the neurotech and psychedelics sectors. The fund actively participates in pre-seed to seed financing rounds, with an initial investment averaging around $200k and the possibility of subsequent investments. The firm actively seeks opportunities in the United States. 
 
The firm actively seeks opportunities in psychoactive therapeutics, CNS therapeutics, neurotech, and techbio. The firm has a neuro focus, and is interested in technologies/products related to CNS disorders, neurodegenerative diseases, neurostimulation and modulation, psychoactive pharmacology, etc. The firm typically invests in drug/therapeutics and medical devices but not so much in digital health. Additionally, the firm looks for cutting edge technologies that demonstrate true, step change or cornerstone innovation instead of incremental improvements on best-in-class technologies. 

The firm is an active investor that supports their portfolio companies with their network and resources. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.